A Phase 2 interventional study of LY2623091 and Tadalafil in Primary Hypertension, sponsored by Eli Lilly and Company. Completed at 43 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-06-26.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Essential Hypertension with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Hypertension · United States.
Among the 53 studies in Essential Hypertension with a site in United States, this one is the 21st largest by enrollment of the 46 interventional ones that give a count, is the only one that started in 2014, is one of 5 in phase 2, and was the 25th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →8 of the 53 studies in Essential Hypertension with a site in United States are open now. Recruiting first, the newest first:
Faith A. Richardson · Sites in United States
Ages 21–80 · Healthy volunteers
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 2–99
ReCor Medical, Inc. · Sites in United States
Ages 18+
Orchestra BioMed, Inc · Sites in United States, Australia, Belgium and 12 more countries
Ages 18+
University of Pittsburgh · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 15 · Phase 4 1
First in 1995; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 304 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 275 across the 46 interventional studies, 1,000 across the 7 observational. Of the 41 that completed or were terminated, 23 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 53 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 1 study filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
3 of the studies in Essential Hypertension with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
| NCT05546931University of PittsburghMobile Health Program for Rural Hypertension | 2026-12 |
| NCT04505618Johns Hopkins UniversityOptical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Essential Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If participants are naïve to treatment of hypertension, or have not been treated with any antihypertensive medications within the 30 days immediately prior to screening:
If participants are currently being treated for hypertension:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
Drug: LY2623091 · Drug: Placebo
13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
Drug: LY2623091 · Drug: Placebo
24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
Drug: LY2623091 · Drug: Placebo
13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
Drug: LY2623091 · Drug: Tadalafil · Drug: Placebo
20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
Drug: Tadalafil · Drug: Placebo
25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
Drug: Spironolactone
Placebo for blinding administered orally once daily for 4 weeks.
Drug: Placebo
Administered orally
Also known as: Mineralocorticoid Receptor Antagonist
Administered orally
Also known as: LY450190
Administered orally
Administered orally
Change From Baseline to 4 Weeks in Seated Systolic Blood Pressure (SBP)
Change from baseline in SBP as measured by a cuff. Least squares (LS) mean change from baseline was calculated using a mixed model repeating measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 4 Weeks
Change From Baseline to 4 Weeks in Seated Diastolic Blood Pressure (DBP)
Change from baseline in DBP as measured by a cuff. LS mean change from baseline was calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 4 Weeks
Change From Baseline to 4 Weeks in 24 Hour Ambulatory Blood Pressure Monitoring (ABPM)
The LS mean change in blood pressure is calculated after adjusting for baseline, treatment and race using an analysis of covariance (ANCOVA).
Time frame: Baseline, 4 Weeks
Change From Baseline to 4 Weeks in Serum Potassium
Potassium measurement as measured by standard laboratory tests. The LS mean change in potassium is calculated using MMRM with adjustment for baseline, treatment, visit, treatment\*visit and race.
Time frame: Baseline, 4 Weeks
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2623091
Time frame: 2 hours post-dose at 4 Weeks
| Milestone | Placebo | 6 Milligrams (mg) LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone |
|---|---|---|---|---|---|---|---|
| Started | 51 | 50 | 52 | 49 | 51 | 25 | 26 |
| Received at least 1 dose of study drug | 51 | 50 | 51 | 49 | 51 | 25 | 26 |
| Completed | 42 | 43 | 44 | 41 | 42 | 21 | 24 |
| Not completed | 9 | 7 | 8 | 8 | 9 | 4 | 2 |
| Withdrew: Adverse event | 6 | 1 | 4 | 4 | 4 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 | 2 | 2 | 1 | 2 |
| Withdrew: Discontinued follow-up period | 0 | 2 | 1 | 0 | 2 | 0 | 0 |
Change from baseline in SBP as measured by a cuff. Least squares (LS) mean change from baseline was calculated using a mixed model repeating measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimeter of mercury (mmHg) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone |
|---|---|---|---|---|---|---|---|
| Change From Baseline to 4 Weeks in Seated Systolic Blood Pressure (SBP) | -0.5 ± 11.6 | -13.1 ± 11.2 | -14.6 ± 12.3 | -14.3 ± 13.6 | -11.8 ± 12.5 | -7.1 ± 13.3 | -15.4 ± 11.7 |
Change from baseline in DBP as measured by a cuff. LS mean change from baseline was calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| mmHg | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone |
|---|---|---|---|---|---|---|---|
| Change From Baseline to 4 Weeks in Seated Diastolic Blood Pressure (DBP) | 0.5 ± 7.9 | -5.6 ± 9.2 | -4.8 ± 7.2 | -7.1 ± 7.6 | -6.8 ± 8.7 | -6.6 ± 8.7 | -1.2 ± 6.1 |
The LS mean change in blood pressure is calculated after adjusting for baseline, treatment and race using an analysis of covariance (ANCOVA).
| mmHg | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone |
|---|---|---|---|---|---|---|---|
| SBP | 0.3 ± 11.3 | -4.9 ± 8.7 | -11.1 ± 8.9 | -10.4 ± 11.4 | -10.4 ± 11.6 | -6.3 ± 8.9 | -6.4 ± 6.8 |
| DBP | 1.0 ± 7.7 | -1.7 ± 6.3 | -4.7 ± 6.1 | -3.4 ± 4.8 | -6.2 ± 8.0 | -5.6 ± 4.9 | -2.0 ± 4.6 |
Potassium measurement as measured by standard laboratory tests. The LS mean change in potassium is calculated using MMRM with adjustment for baseline, treatment, visit, treatment\*visit and race.
| millimoles/L (mmol/L) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone |
|---|---|---|---|---|---|---|---|
| Change From Baseline to 4 Weeks in Serum Potassium | -0.04 ± 0.06 | 0.10 ± 0.06 | 0.11 ± 0.06 | 0.25 ± 0.06 | 0.10 ± 0.06 | -0.06 ± 0.08 | 0.30 ± 0.08 |
| nanogram/milliliter (ng/ml) | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2623091 | 122 ± 32 | 228 ± 37 | 379 ± 51 | 206 ± 53 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/51 (0%) | 23/51 (45.1%) |
| 6 mg LY2623091 | — | 0/50 (0%) | 23/50 (46%) |
| 13 mg LY2623091 | — | 2/51 (3.9%) | 21/51 (41.2%) |
| 24.5 mg LY2623091 | — | 0/49 (0%) | 18/49 (36.7%) |
| 13 mg LY2623091 + 20 mg Tadalafil | — | 1/51 (2%) | 34/51 (66.7%) |
| 20 mg Tadalafil | — | 0/25 (0%) | 14/25 (56%) |
| Spironolactone | — | 0/26 (0%) | 12/26 (46.2%) |
| Event | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone |
|---|---|---|---|---|---|---|---|
| Inguinal herniaGastrointestinal disorders | 0/51 | 0/50 | 0/51 | 0/49 | 1/51 | 0/25 | 0/26 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/51 | 0/50 | 1/51 | 0/49 | 0/51 | 0/25 | 0/26 |
| Diabetic footSkin and subcutaneous tissue disorders | 0/51 | 0/50 | 1/51 | 0/49 | 0/51 | 0/25 | 0/26 |
| Event | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/51 | 5/50 | 2/51 | 1/49 | 10/51 | 3/25 | 0/26 |
| DyspepsiaGastrointestinal disorders | 0/51 | 0/50 | 1/51 | 1/49 | 1/51 | 2/25 | 0/26 |
| NasopharyngitisInfections and infestations | 1/51 | 4/50 | 2/51 | 1/49 | 1/51 | 0/25 | 0/26 |
| DizzinessNervous system disorders | 1/51 | 1/50 | 2/51 | 1/49 | 4/51 | 1/25 | 0/26 |
| NauseaGastrointestinal disorders | 1/51 | 0/50 | 0/51 | 2/49 | 3/51 | 0/25 | 2/26 |
| DiarrhoeaGastrointestinal disorders | 1/51 | 1/50 | 1/51 | 0/49 | 3/51 | 0/25 | 1/26 |
| VomitingGastrointestinal disorders | 0/51 | 1/50 | 0/51 | 0/49 | 3/51 | 0/25 | 0/26 |
| EpididymitisInfections and infestations | 0/35 | 0/33 | 0/27 | 0/29 | 0/30 | 1/17 | 0/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/51 | 0/50 | 0/51 | 0/49 | 3/51 | 0/25 | 0/26 |
| InsomniaPsychiatric disorders | 0/51 | 0/50 | 0/51 | 0/49 | 3/51 | 0/25 | 0/26 |
All randomized participants who received at least 1 dose of a study drug.
| Age, Continuous(years) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 58.6 ± 9.4 | 56.6 ± 11.4 | 58.0 ± 8.8 | 58.7 ± 8.8 | 57.9 ± 9.5 | 54.0 ± 8.9 | 59.0 ± 11.0 | 57.7 ± 9.7 |
| Sex: Female, Male(Participants) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 16 | 17 | 24 | 20 | 21 | 8 | 7 | 113 |
| Male | 35 | 33 | 27 | 29 | 30 | 17 | 19 | 190 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 2 | 2 | 4 | 4 | 1 | 20 |
| Not Hispanic or Latino | 42 | 39 | 45 | 39 | 43 | 19 | 23 | 250 |
| Unknown or Not Reported | 7 | 6 | 4 | 8 | 4 | 2 | 2 | 33 |
| Race (NIH/OMB)(Participants) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 5 |
| Asian | 7 | 4 | 2 | 6 | 2 | 2 | 3 | 26 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 13 | 15 | 14 | 12 | 13 | 7 | 6 | 80 |
| White | 28 | 30 | 34 | 29 | 35 | 15 | 16 | 187 |
| More than one race | 2 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| Canada | 18 | 12 | 9 | 13 | 13 | 5 | 4 | 74 |
| United States | 32 | 36 | 41 | 35 | 38 | 19 | 21 | 222 |
| Puerto Rico | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 7 |
| BMI(kilogram/square meter (kg/m2)) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 30.5 ± 4.5 | 30.2 ± 5.2 | 30.2 ± 4.9 | 32.7 ± 4.5 | 29.5 ± 4.7 | 29.6 ± 4.2 | 31.4 ± 4.5 | 30.6 ± 4.8 |
| Chronic Kidney Disease (CKD)(Participants) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| Y | 0 | 3 | 2 | 0 | 0 | 2 | 2 | 9 |
| N | 51 | 47 | 49 | 49 | 51 | 23 | 24 | 294 |
| Anti-Hypertensive Medication(Participants) | Placebo | 6 mg LY2623091 | 13 mg LY2623091 | 24.5 mg LY2623091 | 13 mg LY2623091 + 20 mg Tadalafil | 20 mg Tadalafil | Spironolactone | Total |
|---|---|---|---|---|---|---|---|---|
| 0 | 8 | 10 | 5 | 7 | 13 | 6 | 3 | 52 |
| 1 | 24 | 22 | 25 | 22 | 17 | 10 | 10 | 130 |
| 2 | 19 | 17 | 20 | 19 | 20 | 8 | 13 | 116 |
| 3 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 4 |
| 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
3 further baseline measures are reported on the registry.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Aug 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2020, 5 years 3 months after primary completion. A results delay was requested in May 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: LY-2623091 · Tadalafil